The partnership between S&R Farmaceutici and the Department of chemistry, biology and biotechnologies of the University of Perugia, directed by Francesco Tarantelli, enters a new, enriching chapter. An agreement has been signed for a ‘Study into the electrophysiological effects of antioxidants on murine blastocysts’, in substance, on fertility.

The partnership will last 18 months (from November 2017) and will receive 9 thousand euros in funding from the company based in Bastia Umbra. This investment will also support the physiology research group under the scientific direction of Dr. Bernard Fioretti. Its president, Romolo Rossi, explains how “One of the interests of S&R farmaceutici is the study and enhancement of antioxidants to promote female fertility. Electrophysical and calcium imaging investigations are required to this effect, skills not currently present in our company”.

Dr. Fioretti specified how “the study will be carried out in the nanomedicine laboratory of which I am director, in particular. In total there will be five researchers working on the project. Some will focus on electrophysiological measurements, others on gene expression and cell culture.”

Recognition for Revifast, a proprietary S&R Farmaceutici molecule, declared best biotechnological product for the year 2017, on occasion of the European Biotechnology Congress in Dubrovnik, Croatia, was undoubtedly a turning point that has inspired both parties to join forces. Dr. Fioretti concluded that “Undoubtedly resveratrol will be one of the antioxidants we will study as part of this partnership, a molecule contained in red wine and the main ingredient of Revifast”.